Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: BNG032
MIFTS: 53

Benign Mesothelioma

Categories: Cancer diseases, Genetic diseases, Rare diseases, Respiratory diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Benign Mesothelioma

About this section

MalaCards integrated aliases for Benign Mesothelioma:

Name: Benign Mesothelioma 12 15
Mesothelioma 44 17 71 32
Benign Tumor of Mesothelium 12
Adenomatoid Tumor 71

Classifications:

MalaCards categories:
Global: Cancer diseases Genetic diseases Rare diseases
Anatomical: Respiratory diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:2645
MeSH 44 D008654
NCIt 50 C3234
SNOMED-CT 67 154491004
ICD10 32 C45 C45.9
UMLS 71 C0025500 C0206675 C1290375
Sources

Summaries for Benign Mesothelioma

About this section
Disease Ontology : 12 A cell type benign neoplasm that has material basis in mesothelium.

MalaCards based summary : Benign Mesothelioma, also known as mesothelioma, is related to malignant peritoneal mesothelioma and benign fibrous mesothelioma, and has symptoms including snoring and coughing. An important gene associated with Benign Mesothelioma is WT1 (WT1 Transcription Factor), and among its related pathways/superpathways are Keratinization and Cytoskeletal Signaling. The drugs Vorinostat and Methylcobalamin have been mentioned in the context of this disorder. Affiliated tissues include testis, t cells and lung, and related phenotypes are cellular and digestive/alimentary

Wikipedia : 74 Mesothelioma is a type of cancer that develops from the thin layer of tissue that covers many of the... more...

Sources

Related Diseases for Benign Mesothelioma

About this section

Diseases in the Benign Mesothelioma family:

Mesothelioma, Malignant Benign Intermediate Mesothelioma

Diseases related to Benign Mesothelioma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1032)
# Related Disease Score Top Affiliating Genes
1 malignant peritoneal mesothelioma 32.6 NF2 CDKN2A
2 benign fibrous mesothelioma 32.3 CD34 CALB2
3 peritoneal mesothelioma 32.2 WT1 THBD NF2 CEACAM5 CDKN2A CALB2
4 malignant epithelial mesothelioma 32.2 THBD CEACAM5 CALB2
5 malignant biphasic mesothelioma 32.0 WT1 THBD MSLN KRT5 CALB2
6 asbestosis 32.0 WT1 THBD MSLN CALB2
7 pericardial mesothelioma 31.9 VIM KRT19 CALB2
8 lymphohistiocytoid mesothelioma 31.9 THBD CEACAM5 CDKN2A CALB2
9 malignant pleural mesothelioma 31.5 WT1 THBD PDPN NKX2-1 NF2 MSLN
10 pleural disease 31.1 NF2 MSLN CEACAM5 CALB2
11 sarcomatoid mesothelioma 31.0 WT1 VIM THBD PDPN NKX2-1 MSLN
12 intestinal obstruction 30.5 KRT7 KRT20 CEACAM5
13 pseudomyxoma peritonei 30.5 KRT7 KRT20 CEACAM5
14 ovarian serous carcinoma 30.5 WT1 KRT7 CALB2
15 pleural cancer 30.5 WT1 NF2 MSLN KRT5 CDKN2A CALB2
16 lung sarcomatoid carcinoma 30.5 THBD NKX2-1 CALB2
17 endosalpingiosis 30.2 WT1 KRT7 CALB2
18 pericardial tuberculosis 30.2 CEACAM5 CALB2
19 appendix adenocarcinoma 30.1 KRT7 KRT20 CEACAM5
20 squamous cell carcinoma 30.1 PDPN KRT7 KRT19 CEACAM5 CDKN2A
21 lung sarcoma 30.1 NKX2-1 CD34 CALB2
22 ovarian cystadenocarcinoma 30.1 CEACAM5 CDKN2A CALB2
23 ovary adenocarcinoma 30.0 WT1 KRT7 CEACAM5 CDKN2A
24 bronchiolo-alveolar adenocarcinoma 30.0 NKX2-1 KRT7 KRT20 CEACAM5
25 cystic lymphangioma 30.0 PECAM1 PDPN CD34 CALB2
26 small cell carcinoma 30.0 NKX2-1 KRT7 KRT20 KRT19 CDKN2A
27 papillary carcinoma 30.0 NKX2-1 KRT7 KRT20 KRT19 CALB2
28 lung squamous cell carcinoma 29.9 PDPN KRT19 GPC3 CDKN2A
29 angiomyoma 29.9 PECAM1 CD34
30 spindle cell sarcoma 29.9 VIM NF2 KRT7 CD34
31 cystadenoma 29.8 KRT7 KRT20 CEACAM5 CALB2
32 mesothelioma, malignant 29.8 WT1 VIM THBD PDPN NKX2-1 NF2
33 meibomian cyst 29.8 KRT7 KRT20
34 secretory meningioma 29.8 VIM NF2 KRT7 CEACAM5
35 lymphangitis 29.7 PECAM1 PDPN NKX2-1 CEACAM5
36 thyroid gland follicular carcinoma 29.7 NKX2-1 KRT7 KRT19 CEACAM5
37 small cell cancer of the lung 29.7 NKX2-1 KRT7 KRT20 KRT19 CEACAM5 CDKN2A
38 intrahepatic cholangiocarcinoma 29.7 KRT7 KRT20 KRT19 GPC3
39 heart sarcoma 29.7 PECAM1 CD34
40 cystadenofibroma 29.7 WT1 KRT7 KRT5 CALB2
41 pericardium cancer 29.7 WT1 MSLN KRT7 KRT5 KRT19 CEACAM5
42 in situ carcinoma 29.7 PDPN KRT5 CDKN2A
43 pneumothorax 29.7 VIM NKX2-1 CALB2
44 cystadenocarcinoma 29.7 VIM PDPN KRT7 CEACAM5
45 pleomorphic carcinoma 29.6 PDPN NKX2-1 KRT7 CALB2
46 gastric diffuse adenocarcinoma 29.6 KRT7 KRT20 CEACAM5
47 papilloma 29.6 KRT7 KRT5 KRT20 CDKN2A
48 lung benign neoplasm 29.6 NKX2-1 KRT7 KRT20 CDKN2A
49 carcinosarcoma 29.6 VIM KRT7 CDKN2A CALB2
50 colorectal adenocarcinoma 29.6 NKX2-1 KRT7 KRT20 CEACAM5 CDKN2A

Graphical network of the top 20 diseases related to Benign Mesothelioma:



Diseases related to Benign Mesothelioma
Sources

Symptoms & Phenotypes for Benign Mesothelioma

About this section

UMLS symptoms related to Benign Mesothelioma:


snoring, coughing

MGI Mouse Phenotypes related to Benign Mesothelioma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10 BCL10 CD34 CDKN2A GPC3 KRT19 KRT7
2 digestive/alimentary MP:0005381 9.76 CDKN2A GPC3 KRT19 KRT5 NKX2-1 PDPN
3 immune system MP:0005387 9.73 BCL10 CD34 CDKN2A GPC3 KRT19 KRT5
4 respiratory system MP:0005388 9.32 CDKN2A GPC3 KRT19 NF2 NKX2-1 PDPN
Sources

Drugs & Therapeutics for Benign Mesothelioma

About this section

Drugs for Benign Mesothelioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 257)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Vorinostat Approved, Investigational Phase 3 149647-78-9 5311
2
Methylcobalamin Approved, Investigational Phase 2, Phase 3 13422-55-4
3
Hydroxocobalamin Approved Phase 2, Phase 3 13422-51-0 11953898 15589840
4
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
5
Ipilimumab Approved Phase 3 477202-00-9
6
Vinorelbine Approved, Investigational Phase 3 71486-22-1 60780 44424639
7
Nintedanib Approved Phase 2, Phase 3 656247-17-5 56843413
8
Cyanocobalamin Approved, Nutraceutical Phase 2, Phase 3 68-19-9 44176380
9 Ranpirnase Investigational Phase 3 196488-72-9
10
Cobalamin Experimental Phase 2, Phase 3 13408-78-1 6857388
11 Histone Deacetylase Inhibitors Phase 3
12 Vitamin B 12 Phase 2, Phase 3
13 Vitamin B12 Phase 2, Phase 3
14 Vitamins Phase 2, Phase 3
15 Interferon-alpha Phase 3
16 Interferon alpha-2 Phase 3
17 Vinca Alkaloids Phase 3
18
Vinblastine Approved Phase 2 865-21-4 13342 241903
19
Heparin Approved, Investigational Phase 2 9005-49-6 772 9812414
20
Megestrol acetate Approved, Investigational, Vet_approved Phase 1, Phase 2 595-33-5 11683
21
Belinostat Approved, Investigational Phase 2 866323-14-0
22
Axitinib Approved, Investigational Phase 1, Phase 2 319460-85-0 6450551
23
Everolimus Approved Phase 2 159351-69-6 6442177 70789204
24
Zoledronic Acid Approved Phase 2 118072-93-8 68740
25
Pancrelipase Approved, Investigational Phase 2 53608-75-6
26
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
27
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
28
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
29
Pentostatin Approved, Investigational Phase 1, Phase 2 53910-25-1 40926 439693
30
Adenosine Approved, Investigational Phase 1, Phase 2 58-61-7 60961
31
Amifostine Approved, Investigational Phase 2 20537-88-6 2141
32
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
33
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3
34
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
35
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
36
Epirubicin Approved Phase 2 56420-45-2 41867
37
Dasatinib Approved, Investigational Phase 2 302962-49-8 3062316
38
Valproic acid Approved, Investigational Phase 2 99-66-1 3121
39
Celecoxib Approved, Investigational Phase 1, Phase 2 169590-42-5 2662
40
Cetuximab Approved Phase 2 205923-56-4 56842117 2333
41
Hydrocortisone acetate Approved, Vet_approved Phase 2 50-03-3
42
Hydrocortisone Approved, Vet_approved Phase 2 50-23-7 5754
43
Sodium citrate Approved, Investigational Phase 2 68-04-2
44
Tamoxifen Approved Phase 2 10540-29-1 2733526
45
Niraparib Approved, Investigational Phase 2 1038915-60-4 24958200
46
Rucaparib Approved, Investigational Phase 2 283173-50-2 9931954
47
Methotrexate Approved Phase 2 1959-05-2, 59-05-2 126941
48
Sargramostim Approved, Investigational Phase 2 123774-72-1, 83869-56-1
49
Raltitrexed Approved, Investigational Phase 1, Phase 2 112887-68-0 104758
50
Decitabine Approved, Investigational Phase 1, Phase 2 2353-33-5 451668

Interventional clinical trials:

(show top 50) (show all 410)
# Name Status NCT ID Phase Drugs
1 Individualized Pemetrexed Dosing in Patients With Non-small Cell Lung Cancer or Mesothelioma Based on Renal Function to Improve Treatment Response Recruiting NCT03655834 Phase 4 Pemetrexed
2 Individualized Pemetrexed Dosing in Patients With Non-small Cell Lung Cancer or Mesothelioma Based on Renal Function to Improve Treatment Response Recruiting NCT03655821 Phase 4 Pemetrexed
3 ONCONASE Plus Doxorubicin Versus Doxorubicin For Patients With Malignant Pleural or Peritoneal Mesothelioma Who Have Had No More Than One Prior Chemotherapy Regimen Unknown status NCT00003034 Phase 3 doxorubicin hydrochloride;ranpirnase
4 NGR015: Randomized Double-blind Phase III Study of NGR-hTNF Plus Best Investigator's Choice (BIC) Versus Placebo Plus BIC in Previously Treated Patients With Advanced Malignant Pleural Mesothelioma (MPM) Completed NCT01098266 Phase 3 NGR-hTNF plus Best Investigator's Choice (BIC);Placebo plus Best Investigator's Choice (BIC)
5 A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Oral Suberoylanilide Hydroxamic Acid (Vorinostat, MK-0683) in Patients With Advanced Malignant Pleural Mesothelioma Previously Treated With Systemic Chemotherapy Completed NCT00128102 Phase 3 Vorinostat;Placebo
6 A Randomized Controlled Trial of Active Symptom Control With or Without Chemotherapy in the Treatment of Patients With Malignant Pleural Mesothelioma Completed NCT00075699 Phase 3 cisplatin;mitomycin C;vincristine sulfate;vinorelbine tartrate
7 Phase III Study of Tomudex and Cisplatin Versus Cisplatin in Malignant Pleural Mesothelioma Completed NCT00004920 Phase 3 cisplatin;raltitrexed
8 A Randomized Phase 3 Trial Comparing ALIMTA Plus Best Supportive Care Versus Best Supportive Care Alone in Previously Treated Patients With Locally Advanced or Metastatic Malignant Pleural Mesothelioma Completed NCT00190762 Phase 3 Pemetrexed
9 A Randomized Study to Assess Whether Radiotherapy Prevents Skin Lumps at Sites Where Needles or Tubes Have Been Inserted in Patients With Malignant Mesothelioma Completed NCT00006231 Phase 3
10 A Single-Blind Randomized Phase III Trial of MTA Plus Cisplatin Versus Cisplatin in Patients With Malignant Pleural Mesothelioma Completed NCT00005636 Phase 3 cisplatin;pemetrexed disodium
11 A Phase II-III Randomized Trial Pemetrexed-Cisplatin Chemotherapy With or Without Bevacizumab (Avastin), 15 mg/kg, for Malignant Pleural Mesothelioma (MPM) Completed NCT00651456 Phase 2, Phase 3 Standard Chemotherapy (Pemetrexed and Cisplatin);Standard Chemotherapy (Pemetrexed and Cisplatin) + Bevacizumab
12 Prospective Randomised Controlled Trial of Video-Assisted Thoracoscopic (VAT) Cytoreductive Pleurectomy Compared to Talc Pleurodesis in Patients With Suspected or Proven Malignant Mesothelioma Completed NCT00821860 Phase 3
13 Randomized Study of Early Palliative Care Integrated With Standard Oncology Care Versus Standard Oncology Care Alone in Patients With Incurable Lung or Non-Colorectal Gastrointestinal Malignancies Completed NCT02349412 Phase 3
14 DREAM3R: DuRvalumab (MEDI4736) With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma - A Phase 3 Randomised Trial Recruiting NCT04334759 Phase 3 Durvalumab;Standard Chemotherapy
15 A Multicentre Randomised Phase III Trial Comparing Atezolizumab Plus Bevacizumab and Standard Chemotherapy Versus Bevacizumab and Standard Chemotherapy as First-line Treatment for Advanced Malignant Pleural Mesothelioma Recruiting NCT03762018 Phase 3 Carboplatin;Pemetrexed;Bevacizumab;Atezolizumab
16 Randomized, Double-Blind, Phase 2/3 Study in Subjects With Malignant Pleural Mesotheliomato Assess ADI-PEG 20 With Pemetrexed and Cisplatin (ATOMIC-Meso Phase 2/3 Study) Recruiting NCT02709512 Phase 2, Phase 3 ADI-PEG 20 plus Pem Cis
17 A Phase 3, Open-Label, Randomized, Parallel Group Study to Evaluate the Efficacy and Safety of Intrapleural Administration of Adenovirus-Delivered Interferon Alpha-2b (rAd-IFN) in Combination With Celecoxib and Gemcitabine in Patients With Malignant Pleural Mesothelioma Recruiting NCT03710876 Phase 3 Celecoxib Oral Product;Gemcitabine
18 Phase III Randomized Trial of Pleurectomy/Decortication Plus Chemotherapy With or Without Adjuvant Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) for Malignant Pleural Mesothelioma (MPM) Recruiting NCT04158141 Phase 3 Carboplatin;Cisplatin;Pemetrexed;Pemetrexed Disodium
19 A Randomized, Open-Label Phase II/III Study With Dendritic Cells Loaded With Allogeneic Tumour Cell Lysate (PheraLys) in Subjects With Mesothelioma as Maintenance Treatment (MesoPher) After Chemotherapy Recruiting NCT03610360 Phase 2, Phase 3 MesoPher
20 CheckpOiNt Blockade For Inhibition of Relapsed Mesothelioma (CONFIRM): A Phase III Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy of Nivolumab in Relapsed Mesothelioma Active, not recruiting NCT03063450 Phase 3 Nivolumab
21 A Phase II/III Randomized Study of Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma Active, not recruiting NCT02784171 Phase 2, Phase 3 Cisplatin;Pemetrexed;Pembrolizumab
22 A Multicentre Randomised Phase III Trial Comparing Pembrolizumab Versus Standard Chemotherapy for Advanced Pre-treated Malignant Pleural Mesothelioma Active, not recruiting NCT02991482 Phase 3 Pembrolizumab;Gemcitabine;Vinorelbine
23 A Phase III, Randomized, Open Label Trial of Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Active, not recruiting NCT02899299 Phase 3 Pemetrexed;Cisplatin;Carboplatin
24 LUME-Meso: Double Blind, Randomised, Multicentre, Phase II/III Study of Nintedanib in Combination With Pemetrexed / Cisplatin Followed by Continuing Nintedanib Monotherapy Versus Placebo in Combination With Pemetrexed / Cisplatin Followed by Continuing Placebo Monotherapy for the Treatment of Patients With Unresectable Malignant Pleural Mesothelioma Terminated NCT01907100 Phase 2, Phase 3 Nintedanib;Pemetrexed;Cisplatin;Cisplatin;Pemetrexed;Placebo
25 PIT: A Phase III Randomised Trial of Prophylactic Irradiation of Tracts in Patients With Malignant Pleural Mesothelioma Following Invasive Chest Wall Intervention Terminated NCT01604005 Phase 3
26 A Randomized Phase III Trial to Compare the Progel Sealant to Standard of Care (SOC) for Patients Undergoing Decortication for Mesothelioma or Other Pathologies Withdrawn NCT02511600 Phase 3
27 Aggressive Multi-Modality Management of Malignant Pleural Mesothelioma Unknown status NCT00354393 Phase 2 cisplatin;methotrexate;vinorelbine ditartrate
28 A Single Arm, Phase II Clinical Study of Tremelimumab Combined With the Anti-PD-L1 MEDI4736 Monoclonal Antibody in Unresectable Malignant Mesothelioma Subjects: The NIBIT-MESO-1 Unknown status NCT02588131 Phase 2 tremelimumab plus MEDI4736
29 A Phase II Study of Milataxel (TL139) Administered Orally in Patients With Malignant Mesothelioma Unknown status NCT00685204 Phase 2 Milataxel
30 A Randomized Stratified Multicentre Phase II Clinical Trial of Single Agent ADI-PEG 20TM (Pegylated Arginine Deiminase) in Patients With Malignant Pleural Mesothelioma Unknown status NCT01279967 Phase 2 ADI-PEG 20
31 Randomized Feasibility Study Of Active Symptom Control With Or Without Chemotherapy In The Treatment Of Patients With Mesothelioma Unknown status NCT00030459 Phase 2 cisplatin;mitomycin C;vinblastine sulfate;vinorelbine tartrate
32 Phase II Trial Of Combined Resection, Intraperitoneal Chemotherapy, And Whole Abdominal Radiation For Treatment Of Peritoneal Mesothelioma Unknown status NCT00024271 Phase 2 cisplatin;doxorubicin hydrochloride;gemcitabine hydrochloride;mitomycin C
33 A Phase II Trial of BIBF 1120 (Nintedanib) in Recurrent Malignant Pleural Mesothelioma Unknown status NCT02568449 Phase 2 Nintedanib
34 A Phase II Study of the Association of Glivec® (Imatinib Mesylate, Formerly Known as STI 571) Plus Gemzar® (Gemcitabine) in Patients With Unresectable, Refractory, Malignant Mesothelioma Expressing Either PDGFR-Beta or C-Kit Unknown status NCT00551252 Phase 2 Imatinib mesylate plus Gemcitabine
35 Phase II Study of Six Hours, Low Dose Gemcitabine Plus Cisplatin in the Treatment for Advanced Pleural Mesothelioma. Unknown status NCT01869023 Phase 2 Gemcitabine;Cisplatin
36 Cisplatin With Either Alimta or Gemcitabine in Long Infusion for Mesothelioma: A Randomised Phase II Trial (AGILI Trial) Unknown status NCT01281800 Phase 2
37 EORTC Randomized Phase II Study of Pleurectomy/ Decortication (P/D) Preceded or Followed by Chemotherapy in Patients With Early Stage Malignant Pleural Mesothelioma Unknown status NCT02436733 Phase 2 Pemetrexed/Cisplatin
38 A SECOND-LINE, SINGLE ARM, PHASE II CLINICAL STUDY WITH TREMELIMUMAB, A FULLY HUMAN ANTI-CTLA-4 MONOCLONAL ANTIBODY, AS MONOTHERAPY IN PATIENTS WITH UNRESECTABLE MALIGNANT MESOTHELIOMA. The MESOT-TREM-2012 Unknown status NCT01655888 Phase 2 Tremelimumab
39 "Phase II Study: Palliative Treatment With Liposomal Doxorubicin Plus Cisplatin for Patients With Malignant Pleural Mesothelioma " Unknown status NCT00886028 Phase 2 Liposomal doxorubicin;Cisplatin
40 Trial of Sorafenib in Malignant Mesothelioma Previously Treated With Platinum-based Chemotherapy Unknown status NCT00794859 Phase 2 Sorafenib
41 A Second-line, Single Arm, Phase II Clinical Study With Tremelimumab, a Fully Human Anti-CTLA-4 Monoclonal Antibody as Monotherapy in Patients With Unresectable Malignant Mesothelioma Unknown status NCT01649024 Phase 2 Tremelimumab
42 A Two Stage, Open Label, Phase II Study of VELCADE Plus ELOXATIN in Previously Treated Patients With Malignant Pleural or Peritoneal Mesothelioma Unknown status NCT00996385 Phase 2 Velcade (bortezomib) plus Eloxatin (oxaliplatin)
43 Four Versus Six Cycles of Pemetrexed/Platinum as a First Line Treatment of Malignant Pleural Mesothelioma; a Randomized Phase II Study Unknown status NCT02497053 Phase 2 pemetrexed/platinum chemotherapy;Pemetrexed/platinum chemotherapy
44 Phase I/II Study of High-Dose Megestrol in Breast or Endometrial Carcinoma or Mesothelioma Unknown status NCT00002465 Phase 1, Phase 2 megestrol acetate
45 A Phase II Trial to Assess the Safety, Immunological Activity of TroVax® Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma Unknown status NCT01569919 Phase 2 Pemetrexed;Cisplatin;Dexamethasone
46 Cytoreductive Surgery Plus Intraoperative Peritoneal Hyperthermic Chemotherapy for the Treatment of Peritoneal Carcinomatosis From Gastrointestinal Cancer: an Open Label, Randomized, Prospective, Phase 2 Clinical Trial Unknown status NCT00454519 Phase 2
47 Therapeutic Efficacy of Wilms' Tumor Gene (WT1) mRNA-electroporated Autologous Dendritic Cell Vaccination in Patients With Solid Tumors: a Phase I/Feasibility Study Unknown status NCT01291420 Phase 1, Phase 2
48 A Randomized Phase I/II Study of Standard Chemotherapy (Cisplatin and Pemetrexed) With or Without Axitinib in Patients With Malignant Mesothelioma: Interim Biopsy Analysis to Determine Efficacy Completed NCT01211275 Phase 1, Phase 2 chemotherapy
49 Tomotherapy Treatment for Mesothelioma Completed NCT00469196 Phase 2
50 Phase II Study of Everolimus (RAD001) for the Treatment of Malignant Pleural Mesothelioma With Merlin/NF2 Loss as a Biomarker to Predict Sensitivity Completed NCT01024946 Phase 2 everolimus

Search NIH Clinical Center for Benign Mesothelioma

Cochrane evidence based reviews: mesothelioma

Sources

Genetic Tests for Benign Mesothelioma

About this section
Sources

Anatomical Context for Benign Mesothelioma

About this section

MalaCards organs/tissues related to Benign Mesothelioma:

40
Testis, T Cells, Lung, Breast, Lymph Node, Endothelial, Atrioventricular Node
Sources

Publications for Benign Mesothelioma

About this section

Articles related to Benign Mesothelioma:

(show top 50) (show all 15522)
# Title Authors PMID Year
1
Lack of Bcl10 mutations in testicular germ cell tumours and derived cell lines. 6
10408400 1999
2
Lack of BCL10 mutations in germ cell tumors and B cell lymphomas. 6
10380920 1999
3
Bcl10 is involved in t(1;14)(p22;q32) of MALT B cell lymphoma and mutated in multiple tumor types. 6
9989495 1999
4
Inactivation of WT1 in nephrogenic rests, genetic precursors to Wilms' tumour. 6
8298644 1993
5
Ultrastructure and observations on the histogenesis of mesotheliomas, "adenomatoid tumors", of the female genital tract. 6
4332312 1972
6
Inhibition of mesothelin-CA-125 interaction in patients with mesothelioma by the anti-mesothelin monoclonal antibody MORAb-009: Implications for cancer therapy. 54 61
19744744 2010
7
Downregulation of Bcl-xL and Mcl-1 is sufficient to induce cell death in mesothelioma cells highly refractory to conventional chemotherapy. 61 54
20142415 2010
8
Development of positron emission tomography imaging by 64Cu-labeled Fab for detecting ERC/mesothelin in a mesothelioma mouse model. 61 54
20072072 2010
9
Serum level of expressed in renal carcinoma (ERC)/ mesothelin in rats with mesothelial proliferative lesions induced by multi-wall carbon nanotube (MWCNT). 54 61
20371980 2010
10
Podoplanin is a useful marker for identifying mesothelioma in malignant effusions. 61 54
20146302 2010
11
Expression of podoplanin and calretinin in meningioma: an immunohistochemical study. 61 54
20425044 2010
12
Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma. 54 61
20075387 2010
13
Survey of British pathologists' performance of mesothelioma post-mortems. 54 61
20092958 2010
14
Soluble mesothelin related peptides (SMRP) and osteopontin as protein biomarkers for malignant mesothelioma: analytical validation of ELISA based assays and characterization at mRNA and protein levels. 54 61
20131968 2010
15
A bipartite butyrate-responsive element in the human calretinin (CALB2) promoter acts as a repressor in colon carcinoma cells but not in mesothelioma cells. 61 54
19998412 2010
16
A flow cytometry method to quantitate internalized immunotoxins shows that taxol synergistically increases cellular immunotoxins uptake. 61 54
20103626 2010
17
The role of folate receptor alpha (FRalpha) in the response of malignant pleural mesothelioma to pemetrexed-containing chemotherapy. 54 61
20051956 2010
18
In vitro and in vivo characterization of highly purified human mesothelioma derived cells. 61 54
20175889 2010
19
CCL2 blockade augments cancer immunotherapy. 54 61
20028856 2010
20
[Malignant peritoneal mesothelioma]. 54 61
20445731 2010
21
Up-regulation of Bcl-xl by hepatocyte growth factor in human mesothelioma cells involves ETS transcription factors. 54 61
19834061 2009
22
Clinical impact and reliability of pleural fluid mesothelin in undiagnosed pleural effusions. 54 61
19299498 2009
23
Malignant pleural mesothelioma: an update on biomarkers and treatment. 61 54
19736192 2009
24
Genome-wide profile of pleural mesothelioma versus parietal and visceral pleura: the emerging gene portrait of the mesothelioma phenotype. 61 54
19662092 2009
25
Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P. 54 61
19671873 2009
26
Osteopontin modulates malignant pleural mesothelioma cell functions in vitro. 61 54
19528482 2009
27
SV40-induced expression of calretinin protects mesothelial cells from asbestos cytotoxicity and may be a key factor contributing to mesothelioma pathogenesis. 54 61
19435792 2009
28
Functional inactivation of NF2/merlin in human mesothelioma. 61 54
18835652 2009
29
Tumorigenic properties of alternative osteopontin isoforms in mesothelioma. 54 61
19285954 2009
30
Selective killing of tumors deficient in methylthioadenosine phosphorylase: a novel strategy. 61 54
19478948 2009
31
Glypican-3 regulates migration, adhesion and actin cytoskeleton organization in mammary tumor cells through Wnt signaling modulation. 61 54
18404367 2009
32
Establishment of novel mAb to human ERC/mesothelin useful for study and diagnosis of ERC/mesothelin-expressing cancers. 61 54
19261093 2009
33
Clinical utility of diagnostic markers for malignant pleural mesothelioma. 61 54
19522163 2009
34
Calretinin: diagnostic utility in the female genital tract. 54 61
19550372 2009
35
Comparison of different clones (WT49 versus 6F-H2) of WT-1 antibodies for immunohistochemical diagnosis of malignant pleural mesothelioma. 54 61
19516197 2009
36
A histone deacetylase inhibitor LBH589 downregulates XIAP in mesothelioma cell lines which is likely responsible for increased apoptosis with TRAIL. 61 54
19179889 2009
37
A phase II multicenter study of L-alanosine, a potent inhibitor of adenine biosynthesis, in patients with MTAP-deficient cancer. 54 61
18618081 2009
38
Mesothelin, Stereocilin, and Otoancorin are predicted to have superhelical structures with ARM-type repeats. 61 54
19128473 2009
39
Pleomorphic carcinoma of the lung expressing podoplanin and calretinin. 61 54
19067851 2008
40
Secretion of N-ERC/mesothelin and expression of C-ERC/mesothelin in human pancreatic ductal carcinoma. 54 61
19020717 2008
41
mTOR mediates survival signals in malignant mesothelioma grown as tumor fragment spheroids. 54 61
18511708 2008
42
YAP1 is involved in mesothelioma development and negatively regulated by Merlin through phosphorylation. 54 61
18725387 2008
43
ERC/mesothelin as a marker for chemotherapeutic response in patients with mesothelioma. 61 54
19192652 2008
44
Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma. 61 54
18670302 2008
45
Mesothelin-related predictive and prognostic factors in malignant mesothelioma: a nested case-control study. 54 61
18281122 2008
46
The value of calretinin and cytokeratin 5/6 as markers for mesothelioma in cell block preparations of serous effusions. 61 54
17916095 2008
47
Malignant mesothelioma 2008. 61 54
18520263 2008
48
Bcl-xL antisense oligonucleotide and cisplatin combination therapy extends survival in SCID mice with established mesothelioma xenografts. 61 54
18360826 2008
49
The value of immunohistochemical expression of TTF-1, CK7 and CK20 in the diagnosis of primary and secondary lung carcinomas. 54 61
18626520 2008
50
Diagnostic importance of 9p21 homozygous deletion in malignant mesotheliomas. 61 54
18327208 2008
Sources

Variations for Benign Mesothelioma

About this section

ClinVar genetic disease variations for Benign Mesothelioma:

6
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 WT1 NM_024426.6(WT1):c.1036A>G (p.Ser346Gly) SNV Pathogenic 3499 rs121907908 11:32421571-32421571 11:32400025-32400025
2 BCL10 NM_003921.5(BCL10):c.136del (p.Ile46fs) Deletion Pathogenic 6263 rs387906351 1:85736511-85736511 1:85270828-85270828
3 BCL10 NM_003921.5(BCL10):c.499dup (p.Ser167fs) Duplication Pathogenic 6250 rs387906350 1:85733512-85733513 1:85267829-85267830
Sources

Expression for Benign Mesothelioma

About this section
Search GEO for disease gene expression data for Benign Mesothelioma.
Sources

Pathways for Benign Mesothelioma

About this section

Pathways related to Benign Mesothelioma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Keratinization 65
Show member pathways
 11.91 KRT7 KRT5 KRT20 KRT19
2
Cytoskeletal Signaling 4
11.66 VIM PDPN NF2 KRT7 KRT5 KRT20
3
Cytoskeleton remodeling Neurofilaments 23
Show member pathways
 11.29 VIM KRT7 KRT5 KRT19
Sources

GO Terms for Benign Mesothelioma

About this section

Cellular components related to Benign Mesothelioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 intermediate filament GO:0005882 9.02 VIM KRT7 KRT5 KRT20 KRT19

Biological processes related to Benign Mesothelioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.77 WT1 VIM NKX2-1 CDKN2A CD34
2 negative regulation of cell proliferation GO:0008285 9.72 WT1 PDPN NF2 GPC3 CDKN2A
3 lung development GO:0030324 9.58 PDPN NKX2-1 GPC3
4 leukocyte migration GO:0050900 9.56 THBD PECAM1 CEACAM5 CD34
5 keratinization GO:0031424 9.46 KRT7 KRT5 KRT20 KRT19
6 negative regulation of blood coagulation GO:0030195 9.43 THBD CD34
7 glomerular endothelium development GO:0072011 8.96 PECAM1 CD34
8 cornification GO:0070268 8.92 KRT7 KRT5 KRT20 KRT19

Molecular functions related to Benign Mesothelioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 structural constituent of cytoskeleton GO:0005200 8.92 VIM KRT5 KRT20 KRT19
Sources

Sources for Benign Mesothelioma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....